search
Back to results

Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus

Primary Purpose

Keratoconus

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Customized Scleral Lens
Sponsored by
University of Rochester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Keratoconus focused on measuring Keratoconus, scleral lens

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

A person will be included in the study if he/she:

  • Is 18 years or older and has full legal capacity to volunteer.
  • Has been diagnosed with Keratoconus;
  • Has no other active ocular disease;
  • Is currently wearing the BostonSight BSS in at least one eye ;
  • Has non-spherical BostonSight BSS haptic design in the study eye;
  • Has 20/400 or better best corrected visual acuity with pinhole 20/60 or better in the study eye;
  • Is not pregnant or nursing;
  • Has voluntarily agreed to participate in the study by signing the statement of informed consent;

A person will be excluded from the study if he/she:

  • Is under the age of 18;
  • Has best corrected visual acuity outside 20/400;
  • Pregnant or nursing at the time of enrollment in the study;

Sites / Locations

  • Flaum Eye Institute, University of Rochester Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Customized Scleral Lens

Arm Description

A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.

Outcomes

Primary Outcome Measures

Number of Participants With Normal Vision
Vision will be tested using the Basic Snellen Visual Acuity test and normal vision will be defined as 20/20.

Secondary Outcome Measures

Full Information

First Posted
August 23, 2018
Last Updated
March 18, 2020
Sponsor
University of Rochester
Collaborators
Ovitz Corporation, Boston Sight
search

1. Study Identification

Unique Protocol Identification Number
NCT03647046
Brief Title
Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
Official Title
Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
October 8, 2018 (Actual)
Primary Completion Date
January 20, 2020 (Actual)
Study Completion Date
January 20, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Rochester
Collaborators
Ovitz Corporation, Boston Sight

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of the study is to examine the effects of custom front-surface wavefront correction on visual performance, and on neutralization of higher order aberrations, in patients wearing a scleral lens device. The investigators will study patients with keratoconus, the most common type of corneal ectasia, who have already been fitted with the BostonSight BSS (Boston Sight Scleral) for improved visual function.
Detailed Description
This study will be a single center, double-masked collection of data taking place at the Flaum Eye Institute. Informed consent will be obtained from all subjects after a thorough explanation of the nature and possible risks of the study. Flaum Eye Institute electronic health records of existing patients will first be screened by an optometrist or ophthalmologist to verify that they do not fall under the exclusion criteria. Some study communication regarding scheduling will be done over the phone or email. The screening will be similar to a standard eye exam (without eye dilation) and will include a slit lamp examination as well as visual acuity and basic vision evaluation. The study eye will be chosen based on inclusion criteria; if both eyes qualify, the eye with worse best corrected acuity will be chosen. A new lens will be manufactured for the subject after the screening visit and will be given to the subject during the following study visit. This is done to ensure fully neutralized spherical refractive effort and positional stability. If screening evaluation reveals that the current lens does not fully neutralize spherical refractive error or that the current lens is not positionally stable, a baseline lens will be manufactured that corrects this. The subject will be allowed to keep the old lens if he or she so chooses. At the second visit, the patient's vision and fit will be evaluated with the optimized baseline BSS lens. Visual acuity and device fit will be evaluated and recorded. If the BSS device fit is still not optimized, then a new device will be made , and the second visit evaluation will be rescheduled. Once the baseline lens design is determined to be satisfactory, the patient will have their wavefront aberration measured with a wavefront sensor. Investigators will dilate the pupil pharmacologically with phenylephrine (2.5%) and tropicamide (1%) and take wavefront measurements of the optical aberrations of the subject's eye wearing the baseline lens using a portable, non-invasive wavefront analyzer designed to measure highly aberrated eyes (Ovitz, P10/EyeProfiler). The investigators will then design and manufacture a study lens that is identical in design to the baseline BostonSight BSS lens except for a custom front surface designed to neutralize the optical aberrations measured with the wavefront analyzer. This HOA-optimized lens will be created prior to the third visit. At the third visit the patient's vision and fit will be evaluated with the new HOA-optimized lens. A designated study team member will measure visual acuity and over-refraction of the patient. If an adjustment is needed for the lens, then a new device will be made, and the third visit evaluation will be rescheduled. Once well-fitting baseline and HOA-optimized test lenses are established, both lenses will be remade and presented to the evaluator designated study team member in charge of evaluation and subject together in a masked fashion. During a fourth visit, the patient's vision will be extensively evaluated using standard non-invasive optometric measurements with each of the two lenses. First the patient will undergo a basic evaluation with each lens to ensure that the fit is correct. The patient will then undergo basic visual acuity; high and low contrast visual acuity, contrast sensitivity, and subjective vision scoring with each lens. The subject's wavefront aberration will also be measured again with each lens.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Keratoconus
Keywords
Keratoconus, scleral lens

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Customized Scleral Lens
Arm Type
Experimental
Arm Description
A customized scleral lens will be compared with a non-customized scleral lens in subjects with Keratoconus through vision tests.
Intervention Type
Device
Intervention Name(s)
Customized Scleral Lens
Intervention Description
A wavefront customized scleral lens will be made for each subject and tested against a non-customized lens.
Primary Outcome Measure Information:
Title
Number of Participants With Normal Vision
Description
Vision will be tested using the Basic Snellen Visual Acuity test and normal vision will be defined as 20/20.
Time Frame
30 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
A person will be included in the study if he/she: Is 18 years or older and has full legal capacity to volunteer. Has been diagnosed with Keratoconus; Has no other active ocular disease; Is currently wearing the BostonSight BSS in at least one eye ; Has non-spherical BostonSight BSS haptic design in the study eye; Has 20/400 or better best corrected visual acuity with pinhole 20/60 or better in the study eye; Is not pregnant or nursing; Has voluntarily agreed to participate in the study by signing the statement of informed consent; A person will be excluded from the study if he/she: Is under the age of 18; Has best corrected visual acuity outside 20/400; Pregnant or nursing at the time of enrollment in the study;
Facility Information:
Facility Name
Flaum Eye Institute, University of Rochester Medical Center
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus

We'll reach out to this number within 24 hrs